|
94 Companies |
|
165 Products |
|
165 Products |
|
42 Mechanisms of Action |
|
2 Trials |
|
1453 News |
|
| «12345678910111213...2930» |
- Enrollment change, Trial withdrawal: Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow (clinicaltrials.gov) - Aug 16, 2016
P=N/A, N=0, Withdrawn, Sponsor: University of Missouri-Columbia
N=400 --> 0 | Completed --> Withdrawn
- ||||||| Repatha (evolocumab) / Amgen, Astellas
Trial completion: GLAGOV: GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound (clinicaltrials.gov) - Aug 16, 2016
P3, N=970, Completed, Sponsor: Amgen
N=400 --> 0 | Completed --> Withdrawn Active, not recruiting --> Completed
- ||||||| evacetrapib (LY2484595) / Eli Lilly
Trial completion, Enrollment change, Combination therapy: A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia (clinicaltrials.gov) - Aug 16, 2016
P3, N=68, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=147 --> 68
- |||| nicotinic acid analog (ARI-3037MO) / Arisaph
Trial completion: Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia (clinicaltrials.gov) - Aug 8, 2016
P2, N=80, Completed, Sponsor: Arisaph Pharmaceuticals Inc
Active, not recruiting --> Completed | N=147 --> 68 Recruiting --> Completed
- Kynamro (mipomersen) / Kastle Therap
Phase classification: Dose-escalating Safety Study in Subjects on Stable Statin Therapy (clinicaltrials.gov) - Aug 3, 2016
P2a, N=74, Completed, Sponsor: Kastle Therapeutics, LLC
Recruiting --> Completed Phase classification: P2 --> P2a
- Trial completion: HCIT-MLD: Imaging Study of the White Matter Lesions in Children With Metachromatic Leucodystrophy (clinicaltrials.gov) - Aug 3, 2016
P=N/A, N=29, Completed, Sponsor: Assistance Publique - H
Phase classification: P2 --> P2a Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Effects of Almond Intake on Atherogenic Lipoprotein Particles (clinicaltrials.gov) - Aug 3, 2016
P=N/A, N=24, Completed, Sponsor: Children's Hospital & Research Center Oakland
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=40 --> 24 | Trial primary completion date: Jun 2016 --> Feb 2016
- Livalo (pitavastatin) / Kowa, Eli Lilly
Trial completion, Trial primary completion date: Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents (clinicaltrials.gov) - Jul 28, 2016
P4, N=120, Completed, Sponsor: Yonsei University
Active, not recruiting --> Completed | N=40 --> 24 | Trial primary completion date: Jun 2016 --> Feb 2016 Recruiting --> Completed | Trial primary completion date: Jul 2012 --> May 2015
- | Trial completion: Mechanisms of Low Levels of Apolipoprotein B (clinicaltrials.gov) - Jul 27, 2016
P=N/A, N=0, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Completed | Trial primary completion date: Jul 2012 --> May 2015 No longer recruiting --> Completed
- | Trial completion: Strong Heart Study (clinicaltrials.gov) - Jul 27, 2016
P=N/A, N=0, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
No longer recruiting --> Completed No longer recruiting --> Completed
- | chlorthalidone / Generic mfg., doxazosin mesylate / Generic mfg., pravastatin / Generic mfg.
Trial completion: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (clinicaltrials.gov) - Jul 27, 2016
P3, N=0, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
No longer recruiting --> Completed No longer recruiting --> Completed
- Trial completion, Trial primary completion date: Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities (clinicaltrials.gov) - Jul 26, 2016
P=N/A, N=57, Completed, Sponsor: Nationwide Children's Hospital
No longer recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jul 2014 --> Jul 2016
- | Trial completion: An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype (clinicaltrials.gov) - Jul 21, 2016
P=N/A, N=49, Completed, Sponsor: Alexion Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Jul 2014 --> Jul 2016 Active, not recruiting --> Completed
- |||| Repatha (evolocumab) / Amgen, Astellas
Trial primary completion date: EBBINGHAUS: Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (clinicaltrials.gov) - Jul 19, 2016
P3, N=1972, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Trial primary completion date: Oct 2017 --> Oct 2016
- pravastatin / Generic mfg.
Enrollment closed: OxLDL: Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome (clinicaltrials.gov) - Jul 12, 2016
P1, N=10, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
Trial primary completion date: Oct 2017 --> Oct 2016 Recruiting --> Active, not recruiting
- ||||||| Tuvero (fimasartan/rosuvastatin) / Boryung Group
Trial completion, Trial primary completion date: A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia (clinicaltrials.gov) - Jul 2, 2016
P3, N=140, Completed, Sponsor: Boryung Pharmaceutical Co., Ltd
Recruiting --> Active, not recruiting Not yet recruiting --> Completed | Trial primary completion date: Jun 2015 --> Sep 2015
- | metformin/rosuvastatin (JLP1310) / Jeil
Trial completion, Trial primary completion date: Clinical Trial to Investigate the Pharmacokinetics Drug Interaction Between Metformin and Rosuvastatin (clinicaltrials.gov) - Jun 27, 2016
P1, N=24, Completed, Sponsor: Jeil Pharmaceutical Co., Ltd.
Not yet recruiting --> Completed | Trial primary completion date: Jun 2015 --> Sep 2015 Not yet recruiting --> Completed | Trial primary completion date: Nov 2014 --> Feb 2015
- recombinant human α-galactosidase A (GC1119) / Green Cross
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Evaluate the Safety and Exploratory Efficacy of GC1119 (clinicaltrials.gov) - Jun 24, 2016
P1, N=8, Completed, Sponsor: Green Cross Corporation
Not yet recruiting --> Completed | Trial primary completion date: Nov 2014 --> Feb 2015 Recruiting --> Completed | N=10 --> 8 | Initiation date: Jul 2012 --> Nov 2012 | Trial primary completion date: Feb 2013 --> May 2014
- Trial completion, Trial primary completion date: Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells (clinicaltrials.gov) - Jun 23, 2016
P1/2, N=25, Completed, Sponsor: Children's Hospital Los Angeles
Recruiting --> Completed | N=10 --> 8 | Initiation date: Jul 2012 --> Nov 2012 | Trial primary completion date: Feb 2013 --> May 2014 Recruiting --> Completed | Trial primary completion date: Aug 2012 --> Aug 2015
- Trial primary completion date: Screening for Fabry Disease in a Pediatric Population at Risk (clinicaltrials.gov) - Jun 21, 2016
P=N/A, N=2000, Recruiting, Sponsor: University Hospital Heidelberg
Recruiting --> Completed | Trial primary completion date: Aug 2012 --> Aug 2015 Trial primary completion date: Jul 2015 --> Dec 2016
- Biomarker, Trial completion: Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis (clinicaltrials.gov) - Jun 17, 2016
P=N/A, N=210, Completed, Sponsor: George Washington University
Trial primary completion date: Jul 2015 --> Dec 2016 Recruiting --> Completed
- ||||||| Kynamro (mipomersen) / Kastle Therap
Trial completion: FOCUS FH: A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol (clinicaltrials.gov) - Jun 16, 2016
P3, N=310, Completed, Sponsor: Genzyme, a Sanofi Company
Recruiting --> Completed Active, not recruiting --> Completed
- || dalcetrapib (JTT-705) / DalCor
Phase classification: A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease (clinicaltrials.gov) - Jun 3, 2016
P3b, N=2220, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Phase classification: P3 --> P3b
- ||||||| bococizumab (RN316) / Pfizer
Trial completion, Enrollment change: SPIRE-FH: A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia (clinicaltrials.gov) - May 27, 2016
P3, N=370, Completed, Sponsor: Pfizer
Phase classification: P3 --> P3b Active, not recruiting --> Completed | N=300 --> 370
- Enrollment change, Trial termination, Trial primary completion date: A Study to Identify and Characterize LAL-D Patients in High-risk Populations (clinicaltrials.gov) - May 25, 2016
P=N/A, N=640, Terminated, Sponsor: Alexion Pharmaceuticals
Active, not recruiting --> Completed | N=300 --> 370 N=10000 --> 640 | Recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Sep 2015
- Enrollment closed: Effects of Almond Intake on Atherogenic Lipoprotein Particles (clinicaltrials.gov) - May 25, 2016
P=N/A, N=40, Active, not recruiting, Sponsor: Children's Hospital & Research Center Oakland
N=10000 --> 640 | Recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Sep 2015 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change: Use of Decision Aids in Clinical Encounters (clinicaltrials.gov) - May 24, 2016
P=N/A, N=62, Completed, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed | N=400 --> 62
- Enrollment change, Trial withdrawal, Trial primary completion date: The Impact of Artichoke Leaf Extract on Blood Cholesterol: Primary Study (clinicaltrials.gov) - May 20, 2016
P=N/A, N=0, Withdrawn, Sponsor: University of Mississippi Medical Center
Enrolling by invitation --> Completed | N=400 --> 62 N=90 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2017 --> Feb 2016
- ||||||| Praluent (alirocumab) / Sanofi, Regeneron
Trial completion: Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan (clinicaltrials.gov) - May 19, 2016
P3, N=199, Completed, Sponsor: Sanofi
N=90 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2017 --> Feb 2016 Active, not recruiting --> Completed
- miglustat / Generic mfg.
Trial completion: Pharmacokinetics and Tolerability of Zavesca (clinicaltrials.gov) - May 19, 2016
P2, N=5, Completed, Sponsor: The Hospital for Sick Children
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ezetimibe / Generic mfg.
Trial completion, Trial primary completion date: The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients (clinicaltrials.gov) - May 19, 2016
P4, N=80, Completed, Sponsor: University Medical Centre Ljubljana
Active, not recruiting --> Completed Not yet recruiting --> Completed | Trial primary completion date: Feb 2015 --> Nov 2015
- Biomarker, Trial completion, Trial primary completion date: Replacement of Saturated Fat in Dairy on Total Cholesterol (clinicaltrials.gov) - May 16, 2016
P=N/A, N=54, Completed, Sponsor: University of Reading
Not yet recruiting --> Completed | Trial primary completion date: Feb 2015 --> Nov 2015 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Apr 2016
- ezetimibe / Generic mfg.
Trial completion: Can Cholesterol Lowering Drugs Influence Circulating Omega-3 Fatty Acid Levels (clinicaltrials.gov) - May 13, 2016
P=N/A, N=60, Completed, Sponsor: University of Manitoba
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Apr 2016 Active, not recruiting --> Completed
- ezetimibe / Generic mfg.
Trial completion, Trial initiation date: Physiological Study of Human Cholesterol Metabolism and Excretion (clinicaltrials.gov) - May 6, 2016
P1, N=132, Completed, Sponsor: Richard E. Ostlund Jr., MD
Active, not recruiting --> Completed Not yet recruiting --> Completed | Initiation date: Sep 2012 --> Jan 2014
- ||||| bococizumab (RN316) / Pfizer
Enrollment change: SPIRE-HR: Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events (clinicaltrials.gov) - Apr 29, 2016
P3, N=727, Completed, Sponsor: Pfizer
Not yet recruiting --> Completed | Initiation date: Sep 2012 --> Jan 2014 N=600 --> 727
- atorvastatin / Generic mfg., rosuvastatin / Generic mfg.
Trial primary completion date: The Therapeutic Effects of Statins and Berberine on the Hyperlipemia (clinicaltrials.gov) - Apr 28, 2016
P4, N=24, Terminated, Sponsor: Wenzhou Medical University
N=600 --> 727 Trial primary completion date: Jun 2015 --> Sep 2015
- | Brineura (cerliponase alfa) / BioMarin
Trial completion: A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease (clinicaltrials.gov) - Apr 27, 2016
P1/2, N=24, Completed, Sponsor: BioMarin Pharmaceutical
Trial primary completion date: Jun 2015 --> Sep 2015 Active, not recruiting --> Completed
- || Enrollment change: The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus (clinicaltrials.gov) - Apr 27, 2016
P=N/A, N=150, Recruiting, Sponsor: Unilever R&D
Active, not recruiting --> Completed N=214 --> 150
- ||||||| bococizumab (RN316) / Pfizer
Trial completion: SPIRE-HR: Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events (clinicaltrials.gov) - Apr 23, 2016
P3, N=600, Completed, Sponsor: Pfizer
N=214 --> 150 Active, not recruiting --> Completed
- Trial primary completion date: IMPACT: Prevention Trial to Achieve Cardiovascular Targets (clinicaltrials.gov) - Apr 15, 2016
P=N/A, N=400, Recruiting, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed Trial primary completion date: Jun 2015 --> Jun 2017
- pradigastat (LCQ908) / Novartis
Trial initiation date: Efficacy of LCQ908 on Cardiovascular Risk (clinicaltrials.gov) - Apr 15, 2016
P2, N=41, Terminated, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2015 --> Jun 2017 Initiation date: Mar 2011 --> Dec 2011
- Trial completion, Enrollment change, Adherence: Genetically Guided Statin Therapy (clinicaltrials.gov) - Apr 14, 2016
P=N/A, N=167, Completed, Sponsor: Duke University
Initiation date: Mar 2011 --> Dec 2011 Recruiting --> Completed | N=375 --> 167
- ||| omega-3 ethylester concentrate / Generic mfg.
Enrollment change: Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia (clinicaltrials.gov) - Apr 4, 2016
P4, N=65, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Completed | N=375 --> 167 N=40 --> 65
- Trial primary completion date: Effect of Rice Bran and Cooked Navy Beans on Cholesterol Levels in Healthy Children (clinicaltrials.gov) - Apr 1, 2016
P=N/A, N=40, Active, not recruiting, Sponsor: Poudre Valley Health System
N=40 --> 65 Trial primary completion date: Jan 2016 --> Jun 2016
- Trial primary completion date: Exploration of Immunity in Gaucher Disease (clinicaltrials.gov) - Mar 29, 2016
P=N/A, N=30, Active, not recruiting, Sponsor: O & O Alpan LLC
Trial primary completion date: Jan 2016 --> Jun 2016 Trial primary completion date: Jul 2015 --> Sep 2016
- Trial completion, Enrollment change, Trial primary completion date: Treatment of Overweight and Obese Children -Using the "Holbaek-Method" in a Municipality Based Treatment Program. (clinicaltrials.gov) - Mar 29, 2016
P=N/A, N=1007, Completed, Sponsor: Holbaek Sygehus
Trial primary completion date: Jul 2015 --> Sep 2016 Recruiting --> Completed | N=800 --> 1007 | Trial primary completion date: Mar 2016 --> Mar 2015
- | Trial completion: Food Matrix and Genetic Variability as Determinants of Bioavailability and Biological Effects of Beta-cryptoxanthin and Phytosterols (clinicaltrials.gov) - Mar 29, 2016
P1, N=40, Completed, Sponsor: Puerta de Hierro University Hospital
Recruiting --> Completed | N=800 --> 1007 | Trial primary completion date: Mar 2016 --> Mar 2015 Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Aug 2015 | Active, not recruiting --> Completed
- | ezetimibe/rosuvastatin (NVP-1205) / Navipharm Corp
Trial completion, Trial primary completion date: Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe (clinicaltrials.gov) - Mar 25, 2016
P1, N=41, Completed, Sponsor: Navipharm Corporation
Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Aug 2015 | Active, not recruiting --> Completed Not yet recruiting --> Completed | Trial primary completion date: Nov 2014 --> Mar 2014
- ||| Trial completion: VASALA: Alpha-linolenic Acid and Blood Pressure (clinicaltrials.gov) - Mar 22, 2016
P=N/A, N=62, Completed, Sponsor: Maastricht University Medical Center
Not yet recruiting --> Completed | Trial primary completion date: Nov 2014 --> Mar 2014 Active, not recruiting --> Completed
- || pradigastat (LCQ908) / Novartis
Trial completion, Trial primary completion date: Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome. (clinicaltrials.gov) - Mar 19, 2016
P3, N=38, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jul 2015